Lu, R., Lumish, H. S., Hasegawa, K., Maurer, M. S., Reilly, M. P., Weiner, S. D., Tower‐Rader, A., Fifer, M. A., & Shimada, Y. J. (2024). Prediction of new‐onset atrial fibrillation in patients with hypertrophic cardiomyopathy using machine learning. European Journal of Heart Failure. Portico. https://doi.org/10.1002/ejhf.3546

Lüsebrink, E., Lanz, H., Kellnar, A., Karam, N., Kapadia, S., Makkar, R., Abraham, W. T., Latib, A., Leon, M., Sannino, A., Shuvy, M., Guerrero, M., Fam, N., Butler, J., Adamo, M., Rudolph, V., Tang, G. H. L., Stocker, T. J., Rommel, K., … Hausleiter, J. (2024). Management of acute decompensated valvular heart disease. European Journal of Heart Failure. Portico. https://doi.org/10.1002/ejhf.3549

Zeldin, L., Eichler, J. B. S., Teruya, S. L., Weinsaft, A. Y., Mirabal, A., Cuomo, M. O., Mateo, K., Helmke, S., & Maurer, M. S. (2024). Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy. European Journal of Heart Failure. Portico. https://doi.org/10.1002/ejhf.3540

Reddy, Y. N. V., Dubrock, H., Hassoun, P. M., Hemnes, A., Horn, E., Leopold, J. A., Rischard, F., Rosenzweig, E. B., Hill, N. S., Erzurum, S. C., Beck, G. J., Mathai, S. C., Mukherjee, M., Tang, W. H. W., Borlaug, B. A., & Frantz, R. P. (2024). Non‐invasive prediction of pulmonary vascular disease‐related exercise intolerance and survival in non‐group 1 pulmonary hypertension. European Journal of Heart Failure. Portico. https://doi.org/10.1002/ejhf.3396

Borlaug, B. A., Larive, B., Frantz, R. P., Hassoun, P., Hemnes, A., Horn, E., Leopold, J., Rischard, F., Berman‐Rosenzweig, E., Beck, G., Erzurum, S., Farha, S., Finet, J. E., Highland, K. B., Jacob, M., Jellis, C., Mehra, R., Renapurkar, R., Singh, H., … Hill, N. (2024). Pulmonary hypertension across the spectrum of left heart and lung disease. European Journal of Heart Failure, 26(7), 1642–1651. Portico. https://doi.org/10.1002/ejhf.3302

Lang, F. M., Teruya, S., Weinsaft, A., Cuomo, M., Santos, A. M., Nalbandian, A., Bampatsias, D., & Maurer, M. S. (2024). Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety. European Journal of Heart Failure, 26(4), 938–947. Portico. https://doi.org/10.1002/ejhf.3198

Garcia‐Pavia, P., Grogan, M., Kale, P., Berk, J. L., Maurer, M. S., Conceição, I., Di Carli, M., Solomon, S. D., Chen, C., Yureneva, E., Vest, J., & Gillmore, J. D. (2024). Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin‐mediated amyloidosis with polyneuropathy. European Journal of Heart Failure, 26(2), 397–410. Portico. https://doi.org/10.1002/ejhf.3138

Russo, G., Badano, L. P., Adamo, M., Alessandrini, H., Andreas, M., Braun, D., Connelly, K. A., Denti, P., Estevez‐Loureiro, R., Fam, N., Gavazzoni, M., Hahn, R. T., Harr, C., Hausleiter, J., Himbert, D., Kalbacher, D., Ho, E., Latib, A., Lubos, E., … Taramasso, M. (2023). Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge‐to‐edge repair – Results from the TriValve registry. European Journal of Heart Failure, 25(12), 2243–2251. Portico. https://doi.org/10.1002/ejhf.3075

Rosenblum, H. R., Griffin, J. M., Minamisawa, M., Prasad, N., Vest, J., White, M. T., Solomon, S. D., Burkhoff, D., & Maurer, M. S. (2023). Effect of patisiran on stroke volume in hereditary transthyretin‐mediated amyloidosis: insights from pressure–volume analysis of the APOLLO study. European Journal of Heart Failure, 25(5), 727–736. Portico. https://doi.org/10.1002/ejhf.2783

Feng, K. Y., Ambrosy, A. P., Zhou, Z., Li, D., Kong, J., Zaroff, J. G., Mishell, J. M., Ku, I. A., Scotti, A., Coisne, A., Redfors, B., Mack, M. J., Abraham, W. T., Lindenfeld, J., & Stone, G. W. (2023). Association between serum albumin and outcomes in heart failure and secondary mitral regurgitation: the COAPT trial. European Journal of Heart Failure, 25(4), 553–561. Portico. https://doi.org/10.1002/ejhf.2809

Varshney, A. S., Berg, D. D., Zhou, G., Sinnenberg, L., Hirji, S., DeFilippis, E. M., Mallidi, H. R., Morrow, D. A., Rinewalt, D., & Givertz, M. M. (2023). Bridging strategies and cardiac replacement outcomes in patients with acute decompensated heart failure‐related cardiogenic shock. European Journal of Heart Failure, 25(3), 425–435. Portico. https://doi.org/10.1002/ejhf.2762

Uriel, N., Milano, C., Agarwal, R., Lee, S., Cleveland, J., Goldstein, D., Wang, A., Crandall, D., & Mehra, M. R. (2022). Incidence and clinical correlates of de‐novo aortic regurgitation with a fully magnetically levitated left ventricular assist device: a MOMENTUM 3 trial portfolio analysis. European Journal of Heart Failure, 25(2), 286–294. Portico. https://doi.org/10.1002/ejhf.2746

Vilches, S., Fontana, M., Gonzalez‐Lopez, E., Mitrani, L., Saturi, G., Renju, M., Griffin, J. M., Caponetti, A., Gnanasampanthan, S., De los Santos, J., Gagliardi, C., Rivas, A., Dominguez, F., Longhi, S., Rapezzi, C., Maurer, M. S., Gillmore, J., & Garcia‐Pavia, P. (2022). Systemic embolism in amyloid transthyretin cardiomyopathy. European Journal of Heart Failure, 24(8), 1387–1396. Portico. https://doi.org/10.1002/ejhf.2566

Frerker, C., Karam, N., Hahn, R. T., Thiele, H., Stone, G. W., Treede, H., & Hausleiter, J. (2022). New ESC/EACTS guideline recommendations for the treatment of secondary mitral regurgitation: reflections on the evidence. European Journal of Heart Failure, 24(5), 746–749. Portico. https://doi.org/10.1002/ejhf.2497